ABLX

Most Recent

  • uploads///ABLYNX_TRANSACTION_HIGHLIGHTS
    Company & Industry Overviews

    Why Sanofi Has Received a Negative Outlook from Fitch Ratings

    Fitch Ratings views Sanofi’s two recent acquisitions in close succession with a total value of 13.7 billion euros as a risk to its balance sheet.

    By Sarah Collins
  • uploads///alx
    Company & Industry Overviews

    How the Ablynx Acquisition Strengthens Sanofi’s R&D Strategy

    Sanofi (SNY) is consistently investing in and focusing on its R&D (research and development) strategy. The company has a number of key technology platforms driving its multitargeting strategy in R&D.

    By Sarah Collins
  • uploads///ABLYNX
    Company & Industry Overviews

    Ablynx Acquisition Strengthens SNY’s Rare Blood Disorder Platform

    Ablynx currently has more than 45 proprietary and partnered programs for the development of new treatments in the therapeutic areas of hematology, inflammation, respiratory disease, oncology, and immuno-oncology.

    By Sarah Collins
  • uploads///ablynx sanofi partnership
    Company & Industry Overviews

    A Look at Ablynx and Sanofi’s Existing Partnership

    On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros.

    By Sarah Collins
  • uploads///ABLYNX_TRANSACTION_HIGHLIGHTS
    Company & Industry Overviews

    Highlights of Sanofi’s 3.9 Billion Euro Ablynx Acquisition

    On January 29, 2018, Sanofi announced its acquisition of Belgium-based Ablynx for 45 euros per share, amounting to a total of 3.9 billion euros (or $4.8 billion) in cash.

    By Sarah Collins
  • uploads///BIOVERATIV_TXN_HIGHLIGHTS
    Company & Industry Overviews

    Sanofi’s $11.6 Billion Bioverativ Acquisition: Highlights

    On January 22, 2018, Sanofi announced that it had entered into an agreement with Bioverativ to acquire all of its outstanding shares for $105 per share in cash.

    By Sarah Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.